5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases-Reference-Cited by-同舟云学术

5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases

Published:2016-03 Issue: Volume:110 Page:291-301
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Vymětalová Ladislava,Havlíček Libor,Šturc Antonín,Skrášková Zuzana,Jorda Radek,Pospíšil Tomáš,Strnad Miroslav,Kryštof Vladimír^ORCID

Funder

Ministry of Education, Youth and Sports of the Czech Republic

Czech Science Foundation

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference36 articles.

1. Cyclin-dependent kinases;Malumbres;Genome Biol.,2014

2. The history and future of targeting cyclin-dependent kinases in cancer therapy;Asghar;Nat. Rev. Drug Discov.,2015

3. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine);McClue;Int. J. Cancer,2002

4. Mechanisms of action of flavopiridol;Sedlacek;Crit. Rev. Oncol. Hematol.,2001

5. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts;Fry;Mol. Cancer Ther.,2004

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The pyrazolo[4,3-c]pyrazole core as a novel and versatile scaffold for developing dual DYRK1A-CLK1 inhibitors targeting key processes of Alzheimer's disease pathology;European Journal of Medicinal Chemistry Reports;2024-12

2. Anticancer and Antibacterial Activeness of Fused Pyrimidines: Newfangled Updates;Bioorganic Chemistry;2024-12

3. Inducing or enhancing protein-protein interaction to develop drugs: Molecular glues with various biological activity;European Journal of Medicinal Chemistry;2024-11

4. Recent Development of CDK2 Inhibitors as Anticancer Drugs: An Update (2015–2023);Pharmaceutical Fronts;2024-09-03

5. Exploration of Potential Cyclin-dependent Kinases and their Inhibitors to Combat Abnormal Signalling and Cancer;Current Signal Transduction Therapy;2024-07